MCRB · XBRL financial data

Seres Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MCRB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	33,215	144,927	7,128	126,325	0	789
Revenue from contracts with customers	11,897	143,857	7,128	—	—	—
Research and development	90,570	141,891	172,920	145,860	64,600	49,060
General and administrative	30,775	69,261	79,694	87,744	53,183	39,156
Total operating expenses	121,345	209,420	253,618	234,308	121,315	94,760
Operating income (loss)	(88,130)	(64,493)	(246,490)	(107,983)	(121,315)	(93,971)
Interest income	946	2,870	3,058	7,301	3,967	2,227
Interest expense	2,924	2,910	6,020	13,176	0	0
Other income (expense)	981	(1,045)	(705)	134	(14,107)	16,755
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(89,127)	(65,578)	(250,157)	(113,724)	136	5,696
Earnings per share, basic‡ USD per share	(22.40)	(14.40)	(46.20)	(17.80)	0.00	0.64
Earnings per share, diluted‡ USD per share	(22.40)	(14.40)	(46.20)	(17.80)	0.00	0.64
Weighted average shares, basic‡ thousands of shares	3,989	4,585	5,404	6,400	7,770	8,859
Weighted average shares, diluted‡ thousands of shares	3,989	4,585	5,404	6,400	7,770	8,870

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (April 2025); filings made before it reported them unadjusted.

Fiscal years (MCRB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	116,049	180,002	163,030	127,965	30,793	45,766
Short-term investments	137,567	110,704	18,311	0	—	—
Accounts receivable	9,387	—	—	—	0	157
Inventory	—	—	0	29,647	—	—
Prepaid and other current assets	5,774	12,922	13,423	9,124	5,813	3,093
Total current assets	268,777	303,628	194,764	175,410	38,674	49,376
Property and equipment, net	13,897	17,938	22,985	22,457	11,534	7,635
Right-of-use asset	9,041	18,208	110,984	109,793	80,903	72,483
Total assets	342,940	354,859	348,784	358,600	139,810	138,193
Accounts payable	4,018	13,735	17,440	3,641	4,079	1,682
Total current liabilities	46,415	82,258	85,596	98,659	41,222	19,322
Lease liability, non-current	10,561	17,958	107,942	105,715	82,966	72,576
Total liabilities	168,190	223,352	338,001	403,456	126,026	93,975
Accumulated deficit	(548,776)	(614,354)	(864,511)	(978,235)	(978,099)	(972,403)
Total stockholders' equity	174,750	131,507	10,783	(44,856)	13,784	44,218
Total liabilities and equity	342,940	354,859	348,784	358,600	139,810	138,193
Common shares outstanding (cover page)‡ thousands of shares	4,577	4,601	6,304	7,550	8,718	9,586

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (April 2025); filings made before it reported them unadjusted.

Fiscal years (MCRB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(89,127)	(65,578)	(250,157)	(113,724)	136	5,696
Stock-based compensation	8,824	20,222	25,482	34,101	20,971	10,840
Depreciation and amortization	6,578	5,947	6,629	6,243	5,468	4,133
Net cash from operating activities	(93,610)	6,688	(228,816)	(117,354)	(148,609)	1,117
Purchases of property and equipment	591	9,566	9,821	7,975	380	252
Net cash from investing activities	(158,891)	64,088	82,428	10,582	142,293	(42)
Proceeds from issuing common stock	243,748	0	96,721	0	0	—
Proceeds from long-term debt	0	0	27,606	—	—	—
Net cash from financing activities	303,424	1,178	129,602	71,705	(90,372)	13,898
Net change in cash	50,923	—	—	—	—	—

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Seres Therapeutics	17,528	593	not reported	10.2M	—	Q3 FY26 10-QSep 30, 2026
Oncolytics Biotech	4,115	not reported	(8,138)*	127.5M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Gyre Therapeutics	43,287	29,105	(16,728)*	111.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Volitionrx	2,800	399	(5,160)*	13.6M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Macrogenics	113,907	32,832	(40,748)*	63.7M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Inovio Pharmaceuticals	31,526	0	(18,047)*	103.4M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
XBiotech	109,528	not reported	(4,515)*	30.5M	24.3 quarters	Q2 FY26 10-QJun 30, 2026
Oramed Pharmaceuticals	15,245	not reported	(200)*	41.6M	80.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.